JAZZ · Jazz Pharmaceuticals plc · Earnings Call Transcripts & Audio
$227.76
-4.59 (-1.98%)
At close · Sep 30
Return incl. dividend (before tax)
Market Cap
$15.45B
Shares
64.91M
Volume · Sep 30
1.01M
Avg daily vol (3M)
862.33K
Jazz Pharmaceuticals plc Earnings Call Transcripts
Quarterly earnings calls for Jazz Pharmaceuticals plc (JAZZ), with available speaker-labelled transcripts, captured audio replays, call highlights, 8-K earnings releases and periodic filings. Investor days and conferences appear here too.
Revenue & result across quarters
Revenue Net income YoY up YoY down artefacts
▲12.2%
$940.65M
−$19.65M
'22 Q3
22-11-09
▲8.4%
$972.12M
−$240.72M
'22 Q4
23-03-01
▲9.7%
$892.81M
$69.42M
'23 Q1
23-05-10
▲2.6%
$957.32M
$104.44M
'23 Q2
23-08-09
▲3.3%
$972.14M
$146.82M
'23 Q3
23-11-08
▲4.1%
$1.01B
$94.15M
'23 Q4
24-01-08
▲1%
$901.98M
−$14.62M
'24 Q1
24-05-01
▲6.9%
$1.02B
$168.57M
'24 Q2
24-07-31
▲8.5%
$1.05B
$215.06M
'24 Q3
24-11-06
▲7.5%
$1.09B
$191.12M
'24 Q4
25-02-25
▼0.5%
$897.80M
−$92.50M
'25 Q1
25-05-06
▲2.1%
$1.05B
−$718.50M
'25 Q2
25-08-27
▲6.7%
$1.13B
$251.41M
'25 Q3
25-11-05
▲10.1%
$1.20B
$203.44M
'25 Q4
26-02-24
▲19.1%
$1.07B
$293.10M
'26 Q1
26-05-05
LATEST
▲15.5%
$1.21B
$192.80M
'26 Q2
26-08-03
Earnings call
FY26 · Q2
2026-08-03
Jazz Pharmaceuticals plc (JAZZ) Q2 2026 Earnings Call Transcript
Confident tone
Epidiolex Franchise and Capsule Launch
Ziihera/Zanidatamab HER2-positive GEA Launch
Xywav Sleep Franchise
Revenue
$1.21B
▲ 15.5% YoY Diluted EPS
$2.78
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-06-03
Jazz Pharmaceuticals plc (JAZZ) June 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-05
Jazz Pharmaceuticals plc (JAZZ) Q1 2026 Earnings Call Transcript
Confident tone
Quarterly commercial performance
ZYHERA (zanidatumab) GEA launch
Pipeline and R&D progress
Revenue
$1.07B
▲ 19.1% YoY Diluted EPS
$4.43
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-02-24
Jazz Pharmaceuticals plc (JAZZ) Q4 2025 Earnings Call Transcript
Confident tone
Zanidatamab pipeline and GEA launch
Rare sleep franchise (Xywav/Xyrem)
Epidiolex growth and patent runway
Revenue
$1.20B*
▲ 10.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-05
Jazz Pharmaceuticals plc (JAZZ) Q3 2025 Earnings Call Transcript
Confident tone
Xywav growth and low-sodium positioning
Zanidatamab HERIZON GEA readout
Modeyso launch and Chimerix acquisition
Revenue
$1.13B
▲ 6.7% YoY Diluted EPS
$4.08
▲ 19.3% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-27
Jazz Pharmaceuticals plc (JAZZ) Q2 2025 Earnings Call Transcript
Positive tone
Financial Guidance
Leadership Transition
Sleep Franchise (Xywav/Xyrem)
Revenue
$1.05B
▲ 2.1% YoY Diluted EPS
$-11.74
▼ 571.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-06
Jazz Pharmaceuticals plc (JAZZ) Q1 2025 Earnings Call Transcript
Confident tone
Zanidatamab pipeline and GEA readout
Dordaviprone and Chimerix acquisition
Xywav and sleep franchise momentum
Revenue
$897.80M
▼ 0.5% YoY Diluted EPS
$-1.52
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-02-25
Jazz Pharmaceuticals plc (JAZZ) Q4 2024 Earnings Call Transcript
Positive tone
Sleep portfolio (Xywav) navigating oxybate competition
Zanidatamab / HERIZON-GEA-01 readout timing delay
Zepzelca first-line SCLC maintenance expansion
Revenue
$1.09B*
▲ 7.5% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-06
Jazz Pharmaceuticals plc (JAZZ) Q3 2024 Earnings Call Transcript
Confident tone
Zanidatamab pipeline
Zepzelca and oncology
Xywav commercial performance
Revenue
$1.05B
▲ 8.5% YoY Diluted EPS
$3.42
▲ 59.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-07-31
Jazz Pharmaceuticals plc (JAZZ) Q2 2024 Earnings Call Transcript
Positive tone
Xywav / oxybate franchise
Oncology (Zepzelca, Rylaze, Zanidatamab)
Epidiolex performance and durability
Revenue
$1.02B
▲ 6.9% YoY Diluted EPS
$2.49
▲ 63.8% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-01
Jazz Pharmaceuticals plc (JAZZ) Q1 2024 Earnings Call Transcript
Confident tone
Xywav / sleep franchise
Oncology portfolio (Zanidatamab, Rylaze, Zepzelca)
Epidiolex growth opportunity
Revenue
$901.98M
▲ 1% YoY Diluted EPS
$-0.23
▼ 122.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q4
2024-01-08
Jazz Pharmaceuticals plc (JAZZ) Q4 2023 Earnings Call Transcript
Confident tone
Zanidatamab pipeline and peak sales potential
Sleep franchise (Xywav / Xyrem / Lumryz competition)
Oncology portfolio (Rylaze and oncology surpassing $1B)
Revenue
$1.01B*
▲ 4.1% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY23 · Q3
2023-11-08
Jazz Pharmaceuticals plc (JAZZ) Q3 2023 Earnings Call Transcript
Revenue
$972.14M
▲ 3.3% YoY Diluted EPS
$2.14
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q2
2023-08-09
Jazz Pharmaceuticals plc (JAZZ) Q2 2023 Earnings Call Transcript
Revenue
$957.32M
▲ 2.6% YoY Diluted EPS
$1.52
▲ 176.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY23 · Q1
2023-05-10
Jazz Pharmaceuticals plc (JAZZ) Q1 2023 Earnings Call Transcript
Revenue
$892.81M
▲ 9.7% YoY Diluted EPS
$1.04
▲ 3366.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q4
2023-03-01
Jazz Pharmaceuticals plc (JAZZ) Q4 2022 Earnings Call Transcript
Revenue
$972.12M*
▲ 8.4% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY22 · Q3
2022-11-09
Jazz Pharmaceuticals plc (JAZZ) Q3 2022 Earnings Call Transcript
Revenue
$940.65M
▲ 12.2% YoY Diluted EPS
$-0.31
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q2
2022-08-03
Jazz Pharmaceuticals plc (JAZZ) Q2 2022 Earnings Call Transcript
Revenue
$932.88M
▲ 24.1% YoY Diluted EPS
$0.55
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY22 · Q1
2022-05-04
Jazz Pharmaceuticals plc (JAZZ) Q1 2022 Earnings Call Transcript
Revenue
$813.72M
▲ 33.9% YoY Diluted EPS
$0.03
▼ 98.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q4
2022-03-01
Jazz Pharmaceuticals plc (JAZZ) Q4 2021 Earnings Call Transcript
Revenue
$896.73M*
▲ 34.7% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY21 · Q3
2021-11-09
Jazz Pharmaceuticals plc (JAZZ) Q3 2021 Earnings Call Transcript
Revenue
$838.12M
▲ 39.5% YoY Diluted EPS
$-0.86
▼ 132.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q2
2021-08-03
Jazz Pharmaceuticals plc (JAZZ) Q2 2021 Earnings Call Transcript
Revenue
$751.81M
▲ 33.7% YoY Diluted EPS
$-6.11
▼ 396.6% YoY
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY21 · Q1
2021-04-20
Jazz Pharmaceuticals plc (JAZZ) Q1 2021 Earnings Call Transcript
Revenue
$607.58M
▲ 13.6% YoY Diluted EPS
$2.09
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q4
2021-02-23
Jazz Pharmaceuticals plc (JAZZ) Q4 2020 Earnings Call Transcript
Revenue
$665.52M
▲ 14.4% YoY Diluted EPS
$2.33
▲ 80.6% YoY Gross margin
91.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY20 · Q3
2020-11-02
Jazz Pharmaceuticals plc (JAZZ) Q3 2020 Earnings Call Transcript
Revenue
$600.89M
▲ 11.8% YoY Diluted EPS
$2.64
▲ 48.3% YoY Gross margin
92.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q2
2020-08-04
Jazz Pharmaceuticals plc (JAZZ) Q2 2020 Earnings Call Transcript
Revenue
$562.44M
▲ 5.3% YoY Diluted EPS
$2.06
▼ 54.8% YoY Gross margin
94.3%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY20 · Q1
2020-05-05
Jazz Pharmaceuticals plc (JAZZ) Q1 2020 Earnings Call Transcript
Revenue
$534.73M
▲ 5.2% YoY Diluted EPS
$-2.82
▼ 291.8% YoY Gross margin
93.8%
Rev · 8q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY19 · Q4
2020-01-14
Jazz Pharmaceuticals plc (JAZZ) Q4 2019 Earnings Call
Revenue
$581.74M
▲ 22.1% YoY Diluted EPS
$1.29
▼ 51.1% YoY Gross margin
93.0%
Rev · 8q
Audio
Transcript
Slides
8-K10-K
Showing 1–28 of 28 earnings calls
Key facts
CIK
1232524
CUSIP
G50871105
13F (30d)
15 filings
13 filers
Visit website
Investor relations